The significance of routine biochemical markers in patients with major depressive disorder

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Peng, You Fan ^a   Xiang, Yang ^a   Wei, Ye Sheng ^a  

^a AFFILIATED HOSPITAL OF YOUJIANG MEDICAL UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989840054     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34402     Document Type: Article

References (40)

1. Gosek, P., Chojnacka, M., Bieskowski, P. & wicicki,. Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression. Psych Pol. 35, 283-294 (2012).
2. Wittchen, H. U. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharm. 21, 655-659 (2011).
3. Michel, T. M. et al. Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study. Eur Psychiatry. 23, 413-420 (2008).
4. Raison, C. L. & Miller, A. H. Is depression an inflammatory disorder? Curr Psychiatry Rep. 13, 467-475 (2010).
5. Michel, T. M., Pülschen, D. & Thome, J. The role of oxidative stress in depressive disorders. Curr Pharm Des. 18, 5890-5899 (2012).
6. Peng, Y. F., Zhong, S. M., Luo, B., Qin, Y. H. & Wei, Y. S. Evaluation of red blood cell distribution width and neutrophil to lymphocyte ratio in patients with major depressive disorder. Int J Clin Exp Med. 9, 3242-3246 (2016).
7. Raison, C. L. et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 70, 31-41 (2013).
8. Muller, N. et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects inmajor: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 11, 680-684 (2006).
9. Lee, J. et al. Proteomic analysis of serum from patients with major depressive disorder to compare their depressive andremission statuses. Psychiatry Investig. 12, 249-59 (2015).
10. Akashi, H. et al. Prefrontal cortex activation is associated with a discrepancy between self-and observer-rated depression severities of major depressive disorder: A multichannel near-infrared spectroscopy study. J. Affect Disord. 174, 165-172 (2015).
11. Gao, M. et al. Use of blood urea nitrogen, creatinine, interleukin-6, granulocyte-ma-crophage colony stimulating factor incombination to predict the severity and outcom-e of abdominal sepsis in rats. Inflamm Res. 61, 889-897 (2012).
12. Peng, Y. F. et al. Association between Serum Fructosamine and Kidney Function in Nondiabetic Individuals without Chronic Kidney Disease. Med Sci Monit. 10, 1996-1999 (2015).
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition. 4th edn. American Psychiatric Association: Washington, DC (2001).
14. Wittchen, H. U. Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): A critical review. J. Psychiatr Res. 28, 57-84 (1994).
15. Hamilton, M. A rating scale for depression. J. Neurol Neurosurg. 23, 56-62 (1960).
16. Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I. & Dalrymple, K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 150, 384e8 (2013).
17. Fridovich, I. Biological effects of the superoxide radical. Arch Biochem Biophys 247, 1-11(1986).
18. Kokacya, M. H., Bahceci, B., Bahceci, I., Dilek, A. R. & Dokuyucu, R. Prolidase activity and oxidative stress in patients with major depressive disorder. Psychiatr Danub. 26, 314-318 (2014).
19. Kodydková, J. et al. Anti-oxidative enzymes and increased oxidative stress in depressive women. Clin Biochem. 42, 1368-1374 (2009).
20. Maciukiewicz, M. et al. Genetic variation in IL-1, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder. Pharmacogenomics. 16, 1919-1929 (2015).
21. Himmerich, H. et al. Regulatory T cells increased while IL-1 decreased during anti-depressant therapy. J. Psychiatr Res. 44, 1052-1057 (2010).
22. Michel, T. M. et al. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder-a postmortem study. Psychiatry Res. 151, 145-50 (2007).
23. Michel, T. M. et al. Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychiatry. 11, 314-20 (2010).
24. Wu, M. L., Ho, Y. C. & Yet, S. F. A central role of heme oxygenase-1 in cardiovascular protection. Antioxid Redox Signal. 15, 1835-1846 (2011).
25. Peng, Y. F., Xie, L. Q., Xiang, Y. & Xu, G. D. Serum bilirubin and their association with C-reactive protein in patients with migraine. J. Clin Lab Anal. 21, doi: 10. 1002/jcla. 21967 (2016).
26. Cervellin, G. et al. Serum bilirubin value predicts hospital admission in carbon monoxide-poisoned patients. Active player or simple bystander? Clinics (Sao Paulo). 70, 628-31 (2015).
27. Cervellin, G., Buonocore, R., Sanchis-Gomar, F. & Lippi, G. Low serum bilirubin values are associated with pulmonary embolism in a case-control study. Clin Chem Lab Med. 7, doi: 10. 1515/cclm-2015-1156 (2016).
28. Peng, Y. F., Wei, Y., Qin, Y. H., Wei, Y. S. & Teng, Y. J. A relationship between absolute monocyte count and C-reactive protein in patients with migraine undergoing no pharmacological therapy. Clin Chem Lab Med. 54, e249-51 (2016).
29. Franchini, M., Targher, G. & Lippi, G. Serum bilirubin levels and cardiovascular disease risk: A Janus Bifrons? Adv Clin Chem. 50, 47-63 (2010).
30. Peng, Y. F., Zhang, L., Pan, G. G. & Wei, Y. S. A potential clinical usefulness of measuring serum bilirubin levels in patients with polymyositis. Eur Rev Med Pharmacol Sci. 20, 631-635 (2016).
31. Lieberman, H. R., Kellogg, M. D., Kramer, F. M., Bathalon, G. P. & Lesher, L. L. Lipid and other plasma markers are associated with anxiety, depression, and fatigue. Health Psychol. 31, 210-216 (2012).
32. Hu, A. et al. Major depressive disorder in hemodialysis pati ents in China. Asia Pac Psychiatry. 7, 78-84 (2015).
33. Brand-Gothelf, A., Leor, S., Apter, A. & Fennig, S. The impact of comorbid depressive and anxiety disorders on severity of anorexia nervosa in adolescent girls. J. Nerv Ment Dis. 202, 759-762 (2014).
34. Whited, M. C. et al. Severity of depressive symptoms and accuracy of dietary reporting among obese women with major depressive disorder seeking weight loss treatment. PLoS One. 28, e90361 (2014).
35. Keane, K. N., Cruzat, V. F., Carlessi, R., de Bittencourt, Jr. P. I. & Newsholme, P. MolecularEvents Linking Oxidative Stress and Inflammation to Insulin Resistance and-Cell Dysfunction. Oxid Med Cell Longev. 18, 1643 (2015).
36. Teachey, M. K. et al. Interactions of conjugated linoleic acid and lipoic acid on insulin action in the obese Zucker rat. Metabolism. 52, 1167-1174 (2003).
37. Urakawa, H. et al. Oxidative stress is associated with adiposity and insulin resistance in men. J. Clin Endocrinol Metab. 88, 4673-4676 (2003).
38. Rudich, A., Kozlovsky, N., Potashnik, R. & Bashan, N. Oxidanttress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol. 272, E935-940 (1997).
39. Gray, J. P. & Heart, E. Usurping the mitochondrial supremacy: extramitochondrial sources of reactive oxygen intermediates and their role in beta cell metabolism and insulin secretion. Toxicol Mech Methods. 20, 167-174 (2010).
40. Zaccardi, F., Kurl, S., Pitocco, D., Ronkainen, K. & Laukkanen, J. A. Serum fructosamine and risk of type 2 diabetes mellitus among middle-age Finnish men: A 23-year population-based prospective study. Acta Diabetologica. 52, 161-166 (2015).